Gilead Sciences, Inc. — GILD
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $121.76 | $151.08B | 18.8 | 13.9 | 10.7% | 7.5% | $3.16 2.6% | 7.0 |
Latest Headlines
- · Ex-Lazard Banker Charged in Insider Trading Case Tied to Health-Care Deals
- · JPM26: HIV pipeline dosing optionality gives Gilead advantage
- · Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing
- · UBS and Citi Go Bullish on Gilead Sciences (GILD)
- · The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration
- · Is Gilead Sciences (GILD) Pricing Reflecting Recent 38.5% One Year Share Return?
Revenue & Net Income
| Date | Revenue | Net Income | EPS | Revenue Change | Net Income Change | EPS Change | |
|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $24.7B | $123.0M | $0.10 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $27.3B | $6.2B | $4.96 | 10.6% | 4961.0% | 4860.0% |
| 2 | 2022-12-31 | $27.3B | $4.6B | $3.66 | -0.1% | -26.2% | -26.2% |
| 3 | 2023-12-31 | $27.1B | $5.7B | $4.54 | -0.6% | 23.4% | 24.0% |
| 4 | 2024-12-31 | $28.8B | $480.0M | $4.54 | 6.0% | -91.5% | 0.0% |
| 5 | TTM 2025-03-31 | $22.1B | $4.7B | $4.76 | -23.3% | 868.8% | 4.8% |
| 6 | Average | -1.5% | 1147.1% | 972.5% |
EPS
Forecasts
Y/Y % Change
GILD Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Average | |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 10.6% | -0.1% | -0.6% | 6.0% | 1.1% | 3.5% | 3.4% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 6 | 6 | |
| EPS Growth (%) | 4961.0% | -26.2% | 23.4% | -91.5% | 2004.2% | 4.9% | 1146.0% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 8 | 8 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | Sales & Marketing ($) | G&A ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|---|---|
| 2021 | $27.3B | $4.6B | $4.6B | $5.2B | $2.0B | ||
| 2022 | $27.3B | $3.6B | $5.0B | $5.7B | $2.1B | ||
| 2023 | $27.1B | $3.8B | $5.7B | $6.1B | $2.7B | ||
| 2024 | $28.8B | $3.5B | $5.9B | $6.1B | $2.8B | ||
| TTM | $29.1B | $3.4B | $5.9B | $2.4B | $1.5B | $5.9B | $2.8B |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|
| 2022 | -0.09 | -21.91 | 8.17 | 8.14 | 2.59 |
| 2023 | -0.60 | 7.06 | 14.89 | 7.35 | 28.06 |
| 2024 | 6.04 | -8.44 | 3.31 | 0.02 | 2.75 |
| TTM | 1.15 | -1.69 | -0.85 | -3.35 | -0.04 |
No unmapped expenses.
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $55,721M |
| 1 | Cash | $5,144M |
| 2 | Total Liabilities | $36,130M |
| 3 | Total Debt | $24,946M |
| 4 | Total Equity | $19,675M |
| 5 | Debt to Equity Ratio | 1.27 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $121.76 | 4.2% | Nicks Growth: 2% Nick's Expected Margin: 15% FINVIZ Growth: 26% |
Nicks: 8 Finviz: 74 |
Nick's: 1.204 | 5.2 | 18.8 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $6.46 EPS | TTM | $51.87 | -57.4% | $475.72 | 290.7% |
| $8.14 EPS | 2025 | $65.36 | -46.3% | $599.44 | 392.3% |
| $8.54 EPS | 2026 | $68.57 | -43.7% | $628.90 | 416.5% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 12.28% | 8.63% | 12.67% | 8.60% | 1.05% | 0.55% | 10.80% | 7.59% | 16.9% | 6.8% |
| 3 Years | 12.28% | 8.63% | 12.67% | 8.60% | 1.05% | 0.55% | 10.80% | 7.59% | 16.9% | 6.8% |
| 5 Years | 12.28% | 8.63% | 12.67% | 8.60% | 1.05% | 0.55% | 10.80% | 7.59% | 16.9% | 6.8% |
| 10 Years | 12.28% | 8.63% | 12.67% | 8.60% | 1.05% | 0.55% | 10.80% | 7.59% | 16.9% | 6.8% |